HCAT vs. EVER, VTEX, DCBO, KIND, SMWB, ARQQ, SPT, SABR, HUYA, and RDVT
Should you be buying Health Catalyst stock or one of its competitors? The main competitors of Health Catalyst include EverQuote (EVER), VTEX (VTEX), Docebo (DCBO), Nextdoor (KIND), Similarweb (SMWB), Arqit Quantum (ARQQ), Sprout Social (SPT), Sabre (SABR), HUYA (HUYA), and Red Violet (RDVT). These companies are all part of the "computer software" industry.
Health Catalyst vs. Its Competitors
Health Catalyst (NASDAQ:HCAT) and EverQuote (NASDAQ:EVER) are both small-cap computer software companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, media sentiment and analyst recommendations.
EverQuote has higher revenue and earnings than Health Catalyst. Health Catalyst is trading at a lower price-to-earnings ratio than EverQuote, indicating that it is currently the more affordable of the two stocks.
EverQuote has a net margin of 7.57% compared to Health Catalyst's net margin of -31.67%. EverQuote's return on equity of 36.90% beat Health Catalyst's return on equity.
Health Catalyst has a beta of 1.62, indicating that its stock price is 62% more volatile than the S&P 500. Comparatively, EverQuote has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500.
85.0% of Health Catalyst shares are held by institutional investors. Comparatively, 91.5% of EverQuote shares are held by institutional investors. 2.6% of Health Catalyst shares are held by insiders. Comparatively, 25.5% of EverQuote shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Health Catalyst presently has a consensus price target of $4.55, suggesting a potential upside of 47.82%. EverQuote has a consensus price target of $32.40, suggesting a potential upside of 65.88%. Given EverQuote's stronger consensus rating and higher probable upside, analysts clearly believe EverQuote is more favorable than Health Catalyst.
In the previous week, EverQuote had 8 more articles in the media than Health Catalyst. MarketBeat recorded 12 mentions for EverQuote and 4 mentions for Health Catalyst. EverQuote's average media sentiment score of 0.64 beat Health Catalyst's score of 0.11 indicating that EverQuote is being referred to more favorably in the news media.
Summary
EverQuote beats Health Catalyst on 16 of the 17 factors compared between the two stocks.
Get Health Catalyst News Delivered to You Automatically
Sign up to receive the latest news and ratings for HCAT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding HCAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Health Catalyst Competitors List
Related Companies and Tools
This page (NASDAQ:HCAT) was last updated on 10/16/2025 by MarketBeat.com Staff
